The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies
- PMID: 9490020
- DOI: 10.1016/s0014-5793(98)00021-0
The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies
Abstract
Bispecific miniantibodies were constructed by genetically fusing the C(H)1 domain of an IgG1 to the C-terminus of a single-chain Fv fragment (scFv-425), specific for the EGF receptor, and fusing the C(L) domain of a kappa light chain to the C-terminus of a scFv specific for CD2 (scFv-M1). An efficient dicistronic gene arrangement for functional expression in Escherichia coli was constructed. Immunoblots demonstrated correct domain assembly and the formation of the natural C(H)1-C(L) disulfide bridge. Gel filtration confirmed the correct size, sandwich ELISAs demonstrated bispecific functionality, and SPR biosensor measurements determined binding to EGF-R in comparison to bivalent constructs. Bispecific anti-EGF-R/anti-CD2 miniantibodies are candidates for the immunotherapy of cancer.
Similar articles
-
A dimeric bispecific miniantibody combines two specificities with avidity.FEBS Lett. 1998 Jul 31;432(1-2):45-9. doi: 10.1016/s0014-5793(98)00829-1. FEBS Lett. 1998. PMID: 9710248
-
Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.Int Immunol. 1998 Dec;10(12):1863-72. doi: 10.1093/intimm/10.12.1863. Int Immunol. 1998. PMID: 9885907
-
Design and production of novel tetravalent bispecific antibodies.Nat Biotechnol. 1997 Feb;15(2):159-63. doi: 10.1038/nbt0297-159. Nat Biotechnol. 1997. PMID: 9035142
-
Bispecific human IgG by design.J Immunol Methods. 2001 Feb 1;248(1-2):7-15. doi: 10.1016/s0022-1759(00)00339-2. J Immunol Methods. 2001. PMID: 11223065 Review.
-
New protein engineering approaches to multivalent and bispecific antibody fragments.Immunotechnology. 1997 Jun;3(2):83-105. doi: 10.1016/s1380-2933(97)00067-5. Immunotechnology. 1997. PMID: 9237094 Review.
Cited by
-
Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.Acta Naturae. 2015 Oct-Dec;7(4):93-6. Acta Naturae. 2015. PMID: 26798495 Free PMC article.
-
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.J Cancer Res Clin Oncol. 2015 Dec;141(12):2079-95. doi: 10.1007/s00432-015-1975-5. Epub 2015 Apr 22. J Cancer Res Clin Oncol. 2015. PMID: 25899161
-
Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.MAbs. 2016 May-Jun;8(4):761-74. doi: 10.1080/19420862.2016.1160180. Epub 2016 Mar 10. MAbs. 2016. PMID: 26963639 Free PMC article.
-
The making of bispecific antibodies.MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. MAbs. 2017. PMID: 28071970 Free PMC article. Review.
-
Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging.PLoS One. 2012;7(10):e48248. doi: 10.1371/journal.pone.0048248. Epub 2012 Oct 25. PLoS One. 2012. PMID: 23133578 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous